NEO Живые сигналы | Максимизируйте прибыль с Getagraph.com

Продать 104936 min ago

@ $14.92

Выпущен: 14 февр. 2024 @ 23:55

Доходность: -5.23%

Предыдущий сигнал: февр. 14 - 22:11

Предыдущий сигнал: Купить

Доходность: 1.53 %

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments...

Stats
Объем за сегодня	787 712
Средний объем	905 165
Рыночная капитализация	1.81B
EPS	$0 ( 2024-02-20 )
Дата следующего отчета о доходах	( $-0.0300 ) 2024-04-30
Last Dividend	$0.400 ( 2020-12-17 )
Next Dividend	$0 ( N/A )
P/E	-20.20
ATR14	$0.0180 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Tetrault Lynn A.	Sell	6 112	Common Stock
2024-02-23	Stone Warren	Buy	42 344	Stock Option (Right to Buy)
2024-02-23	Stone Warren	Buy	25 330	Performance Stock Unit
2024-02-23	Stone Warren	Buy	25 329	Restricted Stock Unit
2024-02-23	Olivo Alicia C	Buy	42 344	Stock Option (Right to Buy)

INSIDER POWER
92.16
Last 88 transactions
Buy: 4 083 000 \| Sell: 279 791

Объем Корреляция

Длинно: -0.40 (neutral)

Кратко: -0.78 (moderate negative)

Signal:(30.143) Neutral

Neogenomics Inc Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Neogenomics Inc Корреляция - Валюта/Сырье

-0.77
( moderate negative )

-0.73
( moderate negative )

0.00
( neutral )

-0.19
( neutral )

0.20
( neutral )

0.01
( neutral )

Neogenomics Inc Финансовые показатели

Annual	2023
Выручка:	$591.64M
Валовая прибыль:	$244.60M (41.34 %)
EPS:	$-0.700

FY	2023
Выручка:	$591.64M
Валовая прибыль:	$244.60M (41.34 %)
EPS:	$-0.700

FY	2022
Выручка:	$509.73M
Валовая прибыль:	$187.90M (36.86 %)
EPS:	$-1.160

FY	2021
Выручка:	$484.33M
Валовая прибыль:	$187.06M (38.62 %)
EPS:	$-0.0700

Financial Reports:

No articles found.

Neogenomics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Neogenomics Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 3.17 - low (5.73%) | Divividend Growth Potential Score: 0.167 - No dividend growth expected in the near future

Information

First Dividend	$0.400	2020-12-17
Last Dividend	$0.400	2020-12-17
Next Dividend	$0	N/A
Payout Date	2020-12-30
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.400	--
Avg. Dividend % Per Year	0.09%	--
Score	0.55	--
Div. Sustainability Score	3.17
Div.Growth Potential Score	0.167
Div. Directional Score	1.670	--

Next Divdend (Est)
(2024-04-27)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.55

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2020	$0.400	1.38%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.149	1.500	-2.97	-4.46	[0 - 0.5]
returnOnAssetsTTM	-0.0523	1.200	-1.744	-2.09	[0 - 0.3]
returnOnEquityTTM	-0.0921	1.500	-2.13	-3.20	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	6.20	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.67	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.56	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.364	-1.500	3.94	-5.90	[0 - 0.6]
interestCoverageTTM	20.01	1.000	3.70	3.70	[3 - 30]
operatingCashFlowPerShareTTM	-0.0155	2.00	-0.00517	-0.0103	[0 - 30]
freeCashFlowPerShareTTM	-0.244	2.00	-0.122	-0.244	[0 - 20]
debtEquityRatioTTM	0.650	-1.500	7.40	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.413	1.000	6.44	6.44	[0.2 - 0.8]
operatingProfitMarginTTM	-0.174	1.000	-5.48	-5.48	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.00319	1.000	-1.129	-1.129	[0.2 - 2]
assetTurnoverTTM	0.352	0.800	-0.987	-0.790	[0.5 - 2]
Total Score				3.17

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-20.24	1.000	-2.15	0	[1 - 100]
returnOnEquityTTM	-0.0921	2.50	-1.372	-3.20	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.244	2.00	-0.0813	-0.244	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.0155	2.00	-0.00517	-0.0103	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	2.32	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.00330	1.000	-2.58	0	[0.1 - 0.5]
Total Score				0.167

Neogenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Обновления в реальном времени для Neogenomics Inc [NEO]

Upcoming Earnings Alert

Neogenomics Inc Dividend Information - No Dividend Player

Dividend Commentary

Top 10 dividend Companies for NASDAQ

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)